NCT02317484View on ClinicalTrials.gov

Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes

CompletedOBSERVATIONAL

Enrollment

231

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

November 21, 2017

Study Completion Date

February 28, 2018

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Ipragliflozin (SGLT2 inhibitor)

Trial Locations (1)

530-0012

Osaka Saiseikai Nakatsu Hospital, Osaka

Sponsors

Collaborators (1)

Astellas Pharma Inc

All Listed Sponsors

collaborator

Osaka Saiseikai Nakatsu Hospital

OTHER

collaborator

Astellas Pharma Inc

INDUSTRY

lead

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

OTHER